» Articles » PMID: 30862606

Drugs Targeting SIRT1, a New Generation of Therapeutics for Osteoporosis and Other Bone Related Disorders?

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2019 Mar 14
PMID 30862606
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

With an aging population and limited treatment options, osteoporosis currently represents a significant public health challenge. Recent animal studies indicate that longevity-associated SIRT1 may serve as an attractive pharmacological target for the treatment of osteoporosis and other bone related disorders. Pre-clinical studies demonstrate that mice treated with SIRT1 agonists show protection against age-related, post-menopausal, and disuse models of osteoporosis. Conversely, SIRT1 knockout models display low bone mass phenotypes associated with increased bone resorption and decreased bone formation. This review summarizes recent animal and human experimental data showing that pharmacological activation of SIRT1 may act in a manner that current treatments do not, namely by treating the imbalance in bone remodeling that is the root cause of osteoporosis and other bone disorders.

Citing Articles

The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.

Zhong S, Huang L, Lin T, Li Y, Deng B, Kong D Iran J Pharm Res. 2025; 23(1):e148139.

PMID: 40066121 PMC: 11892751. DOI: 10.5812/ijpr-148139.


The Sirt1/FOXO signal pathway involves in regulating osteomyelitis progression via modulating mitochondrial dysfunctions and osteogenic differentiation.

Zhang R, Kou N, Liu F, Tong H, Li S, Ren L J Mol Histol. 2025; 56(2):87.

PMID: 39939446 DOI: 10.1007/s10735-025-10370-1.


Bone Adaptations to a Whole Body Vibration Protocol in Murine Models of Different Ages: A Preliminary Study on Structural Changes and Biomarker Evaluation.

Cariati I, Bonanni R, Romagnoli C, Caprioli L, DArcangelo G, Tancredi V J Funct Morphol Kinesiol. 2025; 10(1.

PMID: 39846667 PMC: 11755639. DOI: 10.3390/jfmk10010026.


SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1.

Jin X, Sun X, Ma X, Qin Z, Gao X, Kang X Cell Mol Life Sci. 2024; 81(1):204.

PMID: 38700532 PMC: 11072260. DOI: 10.1007/s00018-023-05043-9.


SIRT1 activation promotes bone repair by enhancing the coupling of type H vessel formation and osteogenesis.

Liu Z, Liu H, Liu S, Li B, Liu Y, Luo E Cell Prolif. 2024; 57(6):e13596.

PMID: 38211965 PMC: 11150139. DOI: 10.1111/cpr.13596.